<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>Proc. Natl. Acad. Sci. USA <br /> Vol. 92, pp. 9687-9691, October 1995 <br /> Biochemistry <br />  <br />  <br /> Characterization functional ordering Slu7p Prpl7p <br /> during second step pre-mRNA splicing yeast <br /> MICHELE HALTINER JoNES, DANIEL N. FRANK*, AND CHRISTINE GUTHRIEt <br /> Department Biochemistry Biophysics, University California, San Francisco, CA 94143 <br />  <br /> Contributed Christine Guthrie, July 7, 1995 <br />  <br /> <span id='am-1' about='protege:abstract' typeof='owl:Thing'>ABSTRACT</span>           Temperature-sensitive alleles genes                      Umen C.G., unpublished work). Furthermore, mutant <br /> (slu7-1, prpl6-2, prpl7-1, prpl8-1) known confer                       alleles PRP17 SLU7 synthetically lethal in <br /> specific block second chemical step pre-mRNA                              combination certain U5 snRNA mutations (7). <br /> splicing vivo yeast Saccharomyces cerevisiae. Previous                       Prpl6p RNA-dependent ATPase shown <br /> studies showed Prpl6p Prpl8p required solely                       effect ATP hydrolysis-dependent conformational rear- <br /> the second step vitro. The RNA-dependent ATPase, Prpl6p,                         rangement 3&apos; splice site (9, 10). In contrast, activity <br /> functions stage splicing ATP required,                      Prpl8p, US snRNP protein, ATP-independent, indi- <br /> Prpl8p functions ATP-independent stage. Here use                           cating Prpl8p acts subsequent Prpl6p (11, 12). Slu7p <br /> immunodepletion roles Slu7p Prpl7p                          contains &quot;zinc knuckle&quot; motif retroviral nucleocapsid <br /> are confined second step splicing. We                      proteins implicated RNA binding; substrate com- <br /> extracts depleted Prpl7p require Prpl7p ATP                         petition experiments suggest SLU7 plays role 3&apos; <br /> slicing complementation, extracts depleted Slu7p                         splice-site choice (13). Prpl7p contains WD-40 motifs, <br /> require addition Slu7p. These different ATP                             present variety proteins thought <span id='am-3' about='protege:TO' typeof='owl:Thing'>to</span> <br /> requirements suggest Prpl6p Prpl7p function                         involved protein-protein interactions (14). In study, <br /> Prpl8p Slu7p. Although SLU7 encodes essential gene                           use antibodies raised Slu7p Prpl7p charac- <br /> product, <span id='am-4' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-5' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-6' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-7' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-8' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-9' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-10' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-11' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-12' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-13' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-14' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-15' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-16' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-17' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-18' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-19' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-20' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-21' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-22' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-23' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-24' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-25' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-26' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-27' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-28' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-29' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-30' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-31' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-32' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-33' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-34' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-35' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-36' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-37' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-38' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-39' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-40' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-41' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-42' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-43' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-44' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-45' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-46' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-47' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-48' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-49' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-50' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-51' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-52' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-53' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-54' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-55' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-56' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-57' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-58' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-59' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-60' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-61' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-62' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-63' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-64' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-65' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-66' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-67' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-68' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-69' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-70' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-71' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-72' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-73' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-74' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-75' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-76' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-77' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-78' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-79' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-80' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-81' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span>null allele</span> prpl7 temperature-                        terize roles splicing vitro perform genetic <br /> sensitive growth partial splicing defect vitro.                    suppression experiments study interactions factors <br /> Finally, high-copy suppression experiments indicate func-                           act second step splicing. <br /> tional interactions PRP16 PRP17, PRP16 and <br /> SLU7, SLU7 PRP18. Taken together, results <br /> suggest factors function multi-                                     MATERIALS AND METHODS <br /> component complex ATP-dependent an <br /> ATP-independent role second step pre-mRNA splic-                            Yeast Strains. The following strains used these <br /> ing.                                                                                studies: yPH274 (15) Mata/atrpl-Ahis3-A200 ura3-52 ade2-101 <br />                                                                                     lys2-801 leu2-Al; BJ2168 (16) Mata leu2 trpl ura3-52prbl-1122 <br /> The removal introns pre-mRNA, termed nuclear                                pep4-3 prcl -407 gal2; BJA 17 (BJ2168 prpl7::LEU2, this <br /> pre-mRNA splicing, highly conserved process occurs                        study); yDFA7 (13) Mata slu7-1 ura3 lys2 his3 ade2 trpl leu2 <br /> in catalytic steps (1, 2). Cleavage 5&apos; splice site                  snr7&amp; :LEU2 pBWURA-SNR7; ts503 (6) Mata prpl8-1 ade2- <br /> trans-esterification reaction followed second trans-                        101 his3-A200 ura3-52 lys2-801; ts365 (6) Mata prpl 7-1 ade2- <br /> esterification reaction results cleavage 3&apos; splice                   101 his3-A200 ura3-52 lys2-801; yS78 [all prpl6 alleles (17)] <br /> site, concomitant ligation exons. Splicing                          Mata trpl ura3 lys2 leu2 ade2 his3 prpl6&amp;.LYS2 pSB2URA- <br /> occurs large complex known spliceosome,                        PRP16; HM121 (U5-A98, H. Madhani, University of <br /> composed numerous proteins small RNAs [Ul, U2,                          California San Francisco) Mata cupl Alys2 leu2 ura3 trpl <br /> U4/U6, U5 small nuclear RNAs (snRNAs)] addition                           his3 snr7/&amp;:LEU2 pSE360-SNR7. <br /> the pre-mRNA. In yeast, non-snRNA factors                               Molecular Biology. All enzymes purchased New <br /> isolated screens temperature-sensitive mutations                        England Biolabs, protocols described (18) <br /> affect splicing (calledprp mutations forpre-mRNAprocessing)                         unless mentioned. <br /> (3).                                                                                  Yeast Genetic Techniques. Growth conditions media, <br />    Our focused studying factors involved                     transformation, plasmid shuffle, tetrad dissection, other <br /> second catalytic step. In yeast mammals, U2, U5, U6                         genetic techniques described (19). <br /> snRNAs shown play roles the                         Overexpression Plasmids. SLU7, PRP17, PRP16 genes <br /> second step splicing (for review, ref. 4). In mammalian                      overexpressed yeast GPD1 promoter the <br /> systems, factor, PTB (pyrimine tract binding protein)-                          multicopy plasmid pG-1 (20). The PRP18 gene expressed <br /> associated splicing factor, binds 3&apos; splice-site pyrimidine                  centromere-containing plasmid (low copy) <span id='am-2' about='protege:FROM' typeof='owl:Thing'>from</span> <br /> tract required vitro second step (5). In yeast,                   D. Horowitz (California Institute Technology). <br /> temperature-sensitive mutations genes reveal role                        Construction PRP17 Gene-Disruption Strain. The PRP17 <br /> the encoded proteins second step splicing vivo:                        clone U. Vijayraghavan, M. Company, J. Abel- <br /> Prpl6p, Prpl7p, Prpl8p, Slu7p (refs. 6 7; review,                       son (California Institute Technology). The disrupted <br /> see ref. 3). In addition, allele U5 snRNP protein                         PRP17 gene contains LEU2 coding sequences, leaving three <br /> encoded PRP8 shown impair 3&apos; splice site                             amino acids PRPJ 7 amino terminus the <br /> recognition inhibit second step (8). Synthetic lethality                    carboxyl terminus. After transformation, gene disruption <br /> is observed alleles genes pairwise                          marked leucine prototrophy confirmed Southern <br /> combination PRP16 PRP18 (ref. 7; J. <br />                                                                                     Abbreviation: snRNA, small nuclear RNA. <br /> The publication costs article defrayed page charge          *Present address: Department Biology, Indiana University, Bloom- <br /> payment. This article marked &quot;advertisement&quot;             ington, IN 47405. <br /> accordance 18 U.S.C. &#194;&#167;1734 solely indicate fact.                       tTo reprint requests addressed. <br />                                                                              9687 <br />  9688      Biochemistry: Jones et al.                                                     Proc. Natl. Acad. Sci. USA 92 (1995) <br /> analysis (18). Ten tetrads diploid strain                      A                                    Plasmid <br /> transformants dissected analyzed. <br />    Prpl7p Slu7p Antibody Production. Polyclonal anti-                                                                      c.1c. <br /> bodies raised fusion proteins containing                                                                 &apos;Ac~c~ <br />                                                                                                                             9999 <br /> Slu7p (described ref. 21) Prpl7p (entire coding sequence) <br /> fused TrpE protein expressed Escherichia coli <br /> (22).                                                                                   T7-STu7p _ <br />    Heterologously Produced Slu7p Prpl7p. Expression                                 Slu7p -_ <br /> Slu7p E. coli preparation extracts accomplished                              Slu7pA -_ <br /> as described (21). Prpl7p produced reticulocyte lysate <br /> using coupled T7 transcription/translation (Pro-                                                       1        2    3     4       5 <br /> mega) programmed pCITE1 (Novagen) pCITE- <br /> PRP17.                                                                                  B               Plasmid <br />    Immunodepletion. Immunodepletion described <br /> (9). Protein A-purified antibodies Prpl6p (9) S.                                                   N <br /> Burgess J. Umen (University California San Fran- <br /> cisco). <br />    In Vitro Splicing. Yeast whole-cell extract prepared,                        Prpl7p _                _ <br /> splicing described (23), reaction temper- <br /> ature 30&#194;&#176;C. Splicing quantitated using Molecular <br /> Dynamics PhosphorImager. Inhibition second step                                              1           2 <br /> complementation block assessed comparing                                                             Plasmid <br /> ratios lariat/lariat-intermediate, lariat-intermediate/mature                        C <br /> mRNA, exon 1/mature mRNA treated sample to <br /> those mock-depleted sample. The ratios gave similar                                                                N <br />                                                                                                                               ~    C&gt;   O <br /> numbers relatively (i.e, a-16 vs. a-7 vs. a-17) terms <br /> of degree complementation.                                                                           9G                9G <br />  <br />               RESULTS AND DISCUSSION <br />    Detection Slu7p Prpl7p Polyclonal Antibod- <br />                                                                                         Prpl7p -_1. <br />                                                                                                                         .1 <br /> ies. To directly assess roles Prpl7p Slu7p                                                1                  2 <br /> second step pre-mRNA splicing, raised polyclonal                     FIG. 1. Detection Slu7p Prpl7p yeast extracts from <br /> antibodies TrpE fusions protein. When                  heterologous sources. (A) Immunoblot analysis (enhanced chemilu- <br /> antibodies used probe immunoblots containing wild-              minescence, Amersham) Slu7p yeast strain BJ2168 <br /> type yeast whole-cell extracts, polypeptides expected            (lanes 1-3) E. coli strain BL21 (lanes 4 5), transformed <br /> sizes Slu7p (44 kDa) Prpl7p (50 kDa) detected               control (lanes 1 5) SLU7-expressing plasmids (lanes <br /> with corresponding antibodies (Fig. 1 A B, respectively,        2-4). Arrows indicate expected migration bacterial, yeast, <br /> lane 1), preimmune serum; substantially greater            truncated yeast proteins, respectively. (B) Immunoblot analysis of <br /> amounts proteins detected extracts           Prpl7p yeast strain BJ2168 transformed control (lane <br /> yeast carrying plasmids overexpressing Slu7p (Fig. 1A,           1) orPRP17 (lane 2)-expressing multicopy plasmids. (C) Fluorography <br /> lane 2) Prpl7p (Fig. iB, lane 2). For Slu7p, correspond-           SDS/PAGE gel containing 35S-labeled reticulocyte lysate vitro <br />                                                                         translation reactions programmed control (lane 1) or <br /> ingly smaller protein detected plasmid bore              PRP17 (lane 2)-expressing plasmids. <br /> truncated version SLU7 gene (Fig. LA, lane 3). Thus, the <br /> antisera specifically recognize Slu7p Prpl7p yeast               similar partial block observed Prpl8p immunode- <br /> whole-cell extracts.                                                    pleted extract (11). <br />    Slu7p Prpl7p Are Only Required Second Step                 To test observed splicing defects resulted from <br /> of Splicing Vitro. We tested effect vitro splicing   specific removal Prpl7p Slu7p removal other <br /> of removing Slu7 Prp17 protein                 coimmunoprecipitating proteins, attempted complemen- <br /> wild-type splicing extract immunodepletion. Two control              tation splicing defects heterologously produced <br /> extracts prepared: treated protein A            Slu7p Prpl7p. To end, synthesized Slu7p E. coli <br /> bound beads (mock) treated antibodies                (T7-Slu7p shown immunoblot analysis Fig. IA, lane 4; <br /> Prp16p (a-16), protein known act second step             note fusion added 14 amino acids) it <br /> splicing vitro. The vitro splicing (and complementation)          complements second-step splicing block seen a-Slu7 <br /> protocol used experiments outlined Fig. 2A.              extracts (Fig. 2B, lane 11), control extract con- <br /> Splicing reactions extracts depleted Prpl6p (a-Prpl6,           taining T7-Slu7p (Fig. LA, lane 5) does (Fig. 2A, lane <br /> lane 3), Slu7p (a-Slu7, lane 9), Prpl7p (a-Prpl7, lane 14) <br /> resulted substantial accumulation first-step splicing         10). Because Prpl7p produced E. coli highly insoluble, we <br /> products (lariat-exon 2 exon 1) decrease               chose synthesize Prpl7p vitro using reticulocyte lysate <br /> products second step (lariat exonl-exon2) relative           transcription-translation system. Prp17 protein visual- <br /> to mock treatment (lane 2). For a-Slu7 a-Prp17                 ized autoradiography radioactive amino acids are <br /> extracts, kinetics splicing assayed revealed         included translation reaction (Fig. 1C, lane 2). This <br /> block step splicing (data shown). Although          protein alleviates second-step block splicing (Fig. 2B, <br /> the second-step block a-Slu7 extract generally close         lane 16), control lysate (Fig. 1C, lane 1) inactive for <br /> complete (i.e., mRNA produced), a-Prp17 extracts              complementation (Fig. 2B, lane 15). Thus, conclude that <br /> a small mRNA formed, despite &gt;90%                  Slu7p Prpl7p specifically required second <br /> removal protein assayed immunoblot analysis (data          step splicing. <br /> not shown). This result suggested small           ATP Requirement Complementation. Previous work has <br /> residual protein conferring partial activity Prpl7p      divided second catalytic step splicing stages: an <br /> is absolutely required second step splicing. A           ATP-dependent stage, defined Prpl6p- <br />              Biochemistry: Jones et aL                                                                         Proc. Natl. Acad. Sci. USA 92 (1995)     9689 <br />                                                          15 5E                                          5 *10_ <br />                    A Extract + *pre-mRNA                --w 1st         Addition (+CC) --w 2nd Addition --mo Stop Splicing <br />                    B                                                                                                c <br />                        M            (t-PRP1 6       Ox-SLU7            (x-PRP17                  Extract             M (t-PRP16 (o-PRP17 <br />                     cc <br />                             - - G G G G         -   -        -   G G    -    -      -         1 st Addition          - G G G - -            - G GG <br />                             - 16 16 16 16 16    -   CC 7         7 7    -   CC 17             2nd Addition           - 16 16 16 - (otA7      (16 <br />                                     A 7 17                         A                                                      A otl6                 A <br />                            ,L,A L                                           A.&amp; I   g                                       _ <br />                                                                                                                                       _MO&quot;o-14 <br />                                                                                         -4-       Q-              P.   .-   , <br />                                                                                                                                    40- -.- wow.   40 <br />  <br />  <br />  <br />  <br />                     1&quot;40                                -1             &apos;1 <br />  <br />  <br />  <br />                    1 2 3 4           5 6 7 8 9 10 11 12 13 14 15 16                     a <br />  <br />  <br />                                                                                                                       1 2 3 4 5 6 7 8 9 <br />  <br />    FIG. 2. In vitro splicing. (A) Diagram general protocol splicing started addition extract components splicing reaction. <br /> (B C) Splicing extracts mock-depleted (protein A treatment alone) (M) immunodepleted Prpl6p (a-PRP16), Slu7p (a-SLU7), <br /> Prpl7p (a-PRP17). CC, excess cold competitor; G, glucose 3 mM; C, control extract (bacterial reticulocyte lysate); A, ATP; 16, purified Prpl6p; <br /> 7, Slu7p-containing bacterial extract; 17, Prpl7p-containing reticulocyte lysate. Arrows B C (top-bottom) indicate migration of <br /> lariat-exon 1, lariat, pre-mRNA, exon 1-exon 2, exon 1, respectively. *, 32P-radiolabeled. <br /> requiring step (9), ATP-independent stage,                                       As expected, complementation Prpl6p (Y. Wang, <br /> which Prpl8p known function (12). The different ATP                                   University California San Francisco) requires addi- <br /> requirements complementation proteins                                      tion ATP glucose treatment (Fig. 2B, compare lanes <br /> formally places Prpl8p-dependent step &quot;downstream&quot;                                   5 6). However, a-Slu7 extract undergoes similar <br /> the Prpl6p-dependent step. We wanted assess ATP                                      treatment deplete ATP, complementation Slu7p pro- <br /> requirement complementation splicing defect                                   ceeds slight reduction exonl- <br /> Slu7p- Prpl7p-immunodepleted extracts functionally                                   exon2 lariat produced (lane 12 vs. lane 11). The addition <br /> order Slu7p Prpl7p relative Prpl6p Prpl8p.                                       ATP (lane 13) does improve complementation and, in <br /> Because yeast splicing extract contains endogenous hexoki-                                  fact, decrease somewhat, probably affecting the <br /> nase, ATP rapidly depleted splicing reactions                                turnover unstable intermediates. That Slu7p fraction <br /> the addition glucose (12). With immunodepleted extracts,                                 itself free ATP shown lane 7 inability to <br /> pre-mRNA incubated splicing conditions allow                                   substitute ATP allowing Prpl6p complementation. <br /> the catalytic step occur (outlined Fig. 2A),                        Thus, Slu7p, like Prpl8p, appears act second step <br />                                                                                             splicing ATP-dependent reactions (e.g., cat- <br /> an excess cold competitor pre-mRNA (CC) added to <br />                                                                                             alyzed Prpl6p). The conclusion reached Ansari <br /> prevent spliceosome assembly, glucose (G) (lst                                  Schwer regarding Slu7p (B. Schwer, personal communi- <br /> addition) added deplete ATP. The complementing                                       cation). <br /> protein added (2nd addition) presence                                       Two alternative approaches taken determine the <br /> absence additional ATP (A). We used extract depleted                                  ATP requirement Prpl7p function. These necessary <br /> Prpl6p control protein known require                                attempts remove ATP reticulocyte <br /> ATP function. We assayed Slu7p Prpl7p                                      lysate-Prpl7p fraction, using dialysis size-exclusion col- <br /> fractions ATP contamination determining                                 umns, inadequate Prpl7p fraction able to <br /> could substitute ATP allowing complementation a-16                                substitute partially ATP Prpl6p complementation <br /> extracts.                                                                                   assay (lane 8). First, used a-Prp16 extract an <br />  9690      Biochemistry: Jones et al.                                                    Proc. Natl. Acad. Sci. USA 92 (1995) <br />  <br /> alternative source Prpl7p (Fig. 2C, complementation of <br /> a-17 shown lane 7 vs. lane 5) a-Prpl7 extract                                                              ESSENTIAL <br />  <br />  <br /> negative control complementation (lane 6). Using a-Prpl6 <br /> extracts complement second-step block a-17 extracts <br /> after glucose treatment requires addition ATP (Fig. 2C,                                                         NON- <br /> lane 9 vs. lane 8). As second approach, reticulocyte                             PR17                  PR18      ESSENTIAL <br />  <br /> lysate-Prpl7p fraction itself treated glucose and <br />                                                                                     ATP-dependent          ATP-independent <br /> exogenous hexokinase, followed dialysis remove glucose. <br /> Although fraction active used Fig. 2B,          FIG. 3. Genetic interactions second-step splicing factors. <br /> lane 16, remaining activity depends ATP addition (data           A line factors indicates synthetic lethal interaction, <br /> not shown). Therefore, Prpl7p appears act                 arrow indicates mutant allele gene the <br /> second step splicing concomitant ATP-              arrowhead suppressed overexpression gene the <br /> dependent reaction. These results allow functionally              beginning arrow. <br /> position Prpl6p Prpl7p Slu7p Prpl8p. <br />    Biological Biochemical Phenotypes PRP17 Gene                  like Prpl8p, Prpl7p essential splicing low tem- <br /> Disruption. The partial vitro splicing defect observed         peratures and, instead, act aiding process that <br /> a-17 extracts despite apparently complete removal            occurs inefficiently higher temperatures. An example <br /> protein prompted determine biological <span id='am-82' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-83' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-84' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-85' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-86' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-87' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-88' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-89' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-90' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-91' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-92' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-93' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-94' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-95' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-96' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-97' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-98' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-99' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-100' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-101' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-102' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-103' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-104' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-105' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-106' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-107' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-108' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-109' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-110' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-111' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-112' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-113' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-114' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-115' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-116' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-117' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-118' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-119' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-120' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-121' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-122' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-123' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-124' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-125' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-126' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-127' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-128' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-129' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-130' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-131' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-132' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-133' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-134' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-135' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-136' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-137' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-138' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-139' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-140' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-141' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-142' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-143' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-144' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-145' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-146' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-147' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-148' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-149' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-150' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-151' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-152' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-153' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-154' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-155' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-156' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-157' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-158' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-159' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span>phenotype</span>            process stabilization functionally <br /> a PRPJ7 gene disruption. We disrupted copy PRP17             active conformation US, U2, U6 snRNAs. <br /> gene nutritional marked LEU2 wild-type diploid               Assessing vivo splicing mRNAs (CYH2, RPS1) <br /> strain (yPH274). The resulting strain sporulated,               prpl7A strain showed identical defect which <br /> tetrads dissected 25&#194;&#176;C; tetrad wild-type        reported prpl7-2 [also called slu4-1 (7)]: constitutive <br /> two slow-growing spores germinated (data shown). The                accumulation lariat intermediate relative mature mRNA <br /> slow-growth phenotype segregated LEU2 marked                   permissive temperature exacerbated shift to <br /> gene disruption. PRPJ7 disrupted wild-type                nonpermissive temperature, decrease the <br /> haploid strain BJ2168, similar results. The resulting haploid      absolute level mRNA (data shown). In vitro splicing <br /> strain (prpl7A) transformed plasmid-borne wild-              using whole-cell extract prpl7A strain shows a <br /> type PRP17 gene (PRP17-pGl) control plasmid (pGl),                 partial block second step similar observed using <br /> and growth 25&#194;&#176;C, 30&#194;&#176;C, 33&#194;&#176;C compared                  immunodepleted extract (data shown). Neither extract <br /> parental wild-type strain (Table 1). Although growth             shows significantly greater defect higher temperature. In <br /> prpl7A&amp; strain (with pG1) similar wild-type strain      summary, genetic removal Prpl7 protein results in <br /> at 25&#194;&#176;C somewhat slow 30&#194;&#176;C, strain inviable            partial growth splicing defects vivo vitro, consis- <br /> 33&#194;&#176;C higher. These phenotypes complemented                tent partial vitro defect observe immu- <br /> prpl7 A strain contains high-copy (PRP1 7-pG1)         nodepletion Prpl7p splicing extract (Fig. 2). <br /> a low-copy (data shown) plasmid-borne wild-type PRP17                  Suppression prp Mutant Phenotypes. Synthetic lethal <br /> gene. A similar temperature-sensitive phenotype                interactions observed alleles pairwise <br /> shown gene disruption PRP18 (11). We conclude that,            combinations second-step factor genes (shown diagrammat- <br />                                                                         ically connecting lines Fig. 3) PRP16 <br /> Table 1. Biological phenotypes splicing mutant strains               PRP18 [ref. 7; J. Umen C.G., unpublished work]. In <br />  Splicing                                      Growth                   complementary approach, examined the <br />  mutant                                                                 growth phenotypes second-step mutants suppressed <br />   allele*         Plasmid           250C        300C           33oCt    overexpression PRP16, PRP17, SLU7 genes. As <br />                                                 +++            +++ <br />                                                                         summarized Table 1 (suppression boldface type) Fig. <br /> Wild type       Any                +++                                  3 (broad arrows), observe partial suppression the <br /> prpl7A&amp;         pG1             <br /> </body></html>